Joe Y Chang: Is Systemic LND Always Necessary In Early-Stage NSCLC?
Joe Y Chang, Professor and Clinical Section Chief at MD Anderson Cancer Center, shared a post on X about a recent article by Yang Zhang at al. published in Journal of Clinical Oncology:
“In early-stage NSCLC, is systemic mediastinal lymph node dissection (LND) always necessary?
No.
Phase III randomized study in JCO 7/2025 showed:
LND increased side effects without improving disease-free survival and OS in patients with ground-glass opacity-dominant adenocarcinoma.”
Title: Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity–Dominant Lung Adenocarcinoma
Authors: Yang Zhang, Bin Qian, Qingping Song, Junjie Ma, Hang Cao, Chaoqiang Deng, Shengping Wang, Ting Ye, Jiaqing Xiang, Yawei Zhang, Yihua Sun, Yueren Yan, Shanbo Zheng, Haoxuan Wu, Qingyuan Huang, Hong Hu, Yuan Li, Fangqiu Fu, Haiquan Chen
Read the Full Article on Journal of Clinical Oncology
More posts featuring Joe Y Chang.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023